Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)

Dane K. Wukich, Nicolaas C. Schaper, Catherine Gooday, Arun Bal, Robert Bem, Avneesh Chhabra, Mary Hastings, Crystal Holmes, Nina L. Petrova, Maria Gala Santini Araujo, Eric Senneville, Katherine M. Raspovic

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The International Working Group on the Diabetic Foot (IWGDF) has published evidence-based guidelines on the prevention and management of diabetic foot disease since 1999. This is the first guideline on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes published by the IWGDF. We followed the GRADE Methodology to devise clinical questions in the PACO (Population, Assessment, Comparison, Outcome) and PICO (Population, Intervention, Comparison, Outcome) format, conducted a systematic review of the medical literature, and developed recommendations with the rationale. The recommendations are based on the evidence from our systematic review, expert opinion when evidence was not available, and also taking into account weighing of the benefits and harms, patient preferences, feasibility and applicability, and costs related to an intervention. We here present the 2023 Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus and also suggest key future topics of research.

Original languageEnglish
Article numbere3646
JournalDiabetes/Metabolism Research and Reviews
Volume40
Issue number3
DOIs
StatePublished - Mar 2024

Keywords

  • Charcot foot
  • Charcot neuro-osteoarthropathy
  • Charcot neuroarthropathy
  • Charcot osteoarthropathy
  • diabetic foot
  • guidelines

Fingerprint

Dive into the research topics of 'Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023)'. Together they form a unique fingerprint.

Cite this